Daiichinkyo Co (TSE:4568) Debt-to-EBITDA : 0.59 (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Daiichinkyo Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円399 Mil. Daiichinkyo Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円101,314 Mil. Daiichinkyo Co's annualized EBITDA for the quarter that ended in Mar. 2024 was 円172,784 Mil. Daiichinkyo Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.59.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Daiichinkyo Co's Debt-to-EBITDA or its related term are showing as below:

TSE:4568' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.33 Med: 1.28 Max: 2.13
Current: 0.33

During the past 13 years, the highest Debt-to-EBITDA Ratio of Daiichinkyo Co was 2.13. The lowest was 0.33. And the median was 1.28.

TSE:4568's Debt-to-EBITDA is ranked better than
76.98% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.675 vs TSE:4568: 0.33

Daiichinkyo Co Debt-to-EBITDA Historical Data

The historical data trend for Daiichinkyo Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Debt-to-EBITDA Chart

Daiichinkyo Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-EBITDA

Get a 7-Day Free Trial

1.11

1.37

1.19

0.70

0.34

Daiichinkyo Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial															1.72	0.59	0.41	0.23	0.59

Competitive Comparison of Daiichinkyo Co's Debt-to-EBITDA

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daiichinkyo Co's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Debt-to-EBITDA falls into.

Daiichinkyo Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Daiichinkyo Co's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(399	+	101314)	/	302906
	=	0.34

Daiichinkyo Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(399	+	101314)	/	172784
	=	0.59

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

Daiichinkyo Co (TSE:4568) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Daiichinkyo Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co (TSE:4568) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (TSE:4568) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

DSNKY:USA DSKYF:USA D4S:Germany

Address

3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426

Website

https://www.daiichisankyo.com

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co (TSE:4568) Headlines

No Headlines